HF-158K1 by HighField Biopharmaceuticals for Pancreatic Cancer: Likelihood of Approval

HF-158K1 is under clinical development by HighField Biopharmaceuticals and currently in Phase I for Pancreatic Cancer.

Eli Lilly, Boehringer Ingelheim get approval to expand Jardiance, Synjardy labels to kids with type 2 diabetes

Eli Lilly and Boehringer Ingelheim won FDA approval to expand empagliflozin’s label to include adolescents with type 2 diabetes. The SGLT2 inhibitor, better known as

June 21, 2023

Numinus Reports Q4 & Full Year Fiscal 2023 Results, Including Greatly Reduced Cash Burn Rate

Psychedelic therapy clinic provider Numinus Wellness (TSX: NUMI) (OTCQX: NUMIF) announced fourth quarter and full year fiscal 2023 results Wednesday after market. The numbers show

November 30, 2023

Challenges associated with return to school after traumatic brain injury

Each year nearly 900,000 US children up to 19 years of age sustain a traumatic brain injury (TBI) requiring hospitalization or emergency treatment.

June 20, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.